NASDAQ:IBRX
ImmunityBio (IBRX)
Financials 
Technical Analysis 
Sep 2, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
ImmunityBio, Inc. has recently experienced a positive turn in its financial performance, reporting earnings of -0.07 USD per share, which surpassed analysts' expectations of -0.11 USD by an impressive 34.66%. The company also achieved a revenue of 32.06 million USD, exceeding the anticipated 31.88 million USD, indicating a strong quarter despite being in the clinical stage of its development. Analysts predict further improvement for the next quarter, expecting earnings of -0.09 USD per share along with an increase in revenue to 37.88 million USD. Additionally, the company has garnered significant attention in social media, with mentions surging up by 1250% in just 24 hours. Founded in 2014 by Patrick Soon-Shiong, ImmunityBio focuses on innovative immunotherapy solutions aimed at combating cancers and infectious diseases, leveraging both innate and adaptive immune responses for long-lasting immunity.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA. Social media mentions are up 31% in the past 24h.
- «
- ‹
- 1
- ›
- »
Popular Articles
ImmunityBio (IBRX) Frequently Asked Questions
What is ImmunityBio stock symbol?
ImmunityBio is a American stock, trading under the symbol IBRX (previously IBRX-Q on Stockchase) on the NASDAQ (IBRX). It is usually referred to as NASDAQ:IBRX or IBRX
Is ImmunityBio a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on IBRX (previously IBRX-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for ImmunityBio.
Is ImmunityBio a good investment or a top pick?
ImmunityBio was recommended as a Top Pick by The Weekly Buzzing Stocks by Billy Kawasaki on 2026-02-19. Read the latest stock experts ratings for ImmunityBio.
Why is ImmunityBio stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for ImmunityBio.
Is ImmunityBio worth watching?
ImmunityBio is covered by Stockchase experts and is worth watching.
What is ImmunityBio stock price?
On 2026-09-03, ImmunityBio (IBRX) stock closed at a price of $8.19.
In the last quarter, the company reported -0.07 USD per share, beating the -0.11 USD estimate by 34.66%. Revenue for the same period reached 32.06 M USD, despite the estimate of 31.88 M USD. For the next quarter, analysts expect -0.09 USD in earnings per share and 37.88 M USD in revenue. Social media mentions are up 1250% in the past 24h.